AR007004A1 - Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen - Google Patents

Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen

Info

Publication number
AR007004A1
AR007004A1 ARP970101856A ARP970101856A AR007004A1 AR 007004 A1 AR007004 A1 AR 007004A1 AR P970101856 A ARP970101856 A AR P970101856A AR P970101856 A ARP970101856 A AR P970101856A AR 007004 A1 AR007004 A1 AR 007004A1
Authority
AR
Argentina
Prior art keywords
piperazinyl
dihydro
ethyl
pharmaceutical compositions
benzoisotiazol
Prior art date
Application number
ARP970101856A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR007004A1 publication Critical patent/AR007004A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Se refiere a las sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2H-indol-2-ona dihidratadas, acomposiciones farmacéuticas que contienen dichas sales metanosulfonato hidratadas. La fig.1representa el espectro de difracción de polvo de rayos Xde metanosulfonato de ziprasidona dihidratado (cristal alargado) expresado como la intensidad (Cps) frente al ángulo de difracción (grados 20).
ARP970101856A 1996-05-07 1997-05-05 Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen AR007004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
AR007004A1 true AR007004A1 (es) 1999-10-13

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101856A AR007004A1 (es) 1996-05-07 1997-05-05 Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen

Country Status (41)

Country Link
US (1) US6245765B1 (es)
EP (1) EP0918772B1 (es)
JP (1) JP3494659B2 (es)
KR (1) KR100333215B1 (es)
CN (1) CN1091769C (es)
AP (1) AP765A (es)
AR (1) AR007004A1 (es)
AT (1) ATE278689T1 (es)
AU (1) AU731267B2 (es)
BG (1) BG63544B1 (es)
BR (1) BR9709889A (es)
CA (1) CA2252898C (es)
CO (1) CO4940466A1 (es)
CZ (1) CZ289215B6 (es)
DE (1) DE69731094T2 (es)
DK (1) DK0918772T3 (es)
DZ (1) DZ2222A1 (es)
EA (1) EA001190B1 (es)
EG (1) EG24076A (es)
ES (1) ES2229342T3 (es)
GT (1) GT199700052A (es)
HK (1) HK1017892A1 (es)
HR (1) HRP970236B1 (es)
ID (1) ID16867A (es)
IL (1) IL126591A (es)
IS (1) IS2080B (es)
MA (1) MA24171A1 (es)
MY (1) MY119997A (es)
NO (1) NO312514B1 (es)
NZ (1) NZ332218A (es)
OA (1) OA10909A (es)
PL (1) PL188330B1 (es)
PT (1) PT918772E (es)
SI (1) SI0918772T1 (es)
SK (1) SK282837B6 (es)
TN (1) TNSN97074A1 (es)
TR (1) TR199802240T2 (es)
TW (1) TW491847B (es)
UA (1) UA46840C2 (es)
WO (1) WO1997042191A1 (es)
ZA (1) ZA973876B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
NZ551012A (en) * 2000-06-02 2008-04-30 Pfizer Prod Inc Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
JP2006528676A (ja) 2003-05-16 2006-12-21 ファイザー・プロダクツ・インク 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
CA2599391A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PL188164B1 (pl) 1996-05-07 2004-12-31 Pfizer Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny

Also Published As

Publication number Publication date
TW491847B (en) 2002-06-21
MY119997A (en) 2005-08-30
AU731267B2 (en) 2001-03-29
US6245765B1 (en) 2001-06-12
AP9700976A0 (en) 1997-07-31
CN1091769C (zh) 2002-10-02
AP765A (en) 1999-09-17
PL329884A1 (en) 1999-04-12
MA24171A1 (fr) 1997-12-31
GT199700052A (es) 2001-08-29
EA001190B1 (ru) 2000-12-25
KR20000010824A (ko) 2000-02-25
ES2229342T3 (es) 2005-04-16
CN1216991A (zh) 1999-05-19
CZ349398A3 (cs) 1999-09-15
CA2252898A1 (en) 1997-11-13
CZ289215B6 (cs) 2001-12-12
ATE278689T1 (de) 2004-10-15
ID16867A (id) 1997-11-20
BG102892A (en) 1999-09-30
NO985194D0 (no) 1998-11-06
PT918772E (pt) 2004-12-31
OA10909A (en) 2001-10-26
DZ2222A1 (fr) 2002-12-03
WO1997042191A1 (en) 1997-11-13
CO4940466A1 (es) 2000-07-24
UA46840C2 (uk) 2002-06-17
NZ332218A (en) 2005-02-25
EP0918772B1 (en) 2004-10-06
DK0918772T3 (da) 2005-01-10
HK1017892A1 (en) 1999-12-03
AU2174797A (en) 1997-11-26
BG63544B1 (bg) 2002-04-30
TNSN97074A1 (fr) 2005-03-15
KR100333215B1 (ko) 2002-06-20
NO985194L (no) 1998-11-06
IS2080B (is) 2006-02-15
DE69731094T2 (de) 2006-02-23
SI0918772T1 (en) 2005-02-28
EG24076A (en) 2008-05-11
SK150898A3 (en) 2000-02-14
JP3494659B2 (ja) 2004-02-09
ZA973876B (en) 1998-11-06
IS4874A (is) 1998-10-20
JPH11509867A (ja) 1999-08-31
IL126591A (en) 2001-11-25
DE69731094D1 (de) 2004-11-11
CA2252898C (en) 2003-04-08
NO312514B1 (no) 2002-05-21
EP0918772A1 (en) 1999-06-02
EA199800912A1 (ru) 1999-04-29
PL188330B1 (pl) 2005-01-31
HRP970236B1 (en) 2002-12-31
HRP970236A2 (en) 1998-06-30
SK282837B6 (sk) 2002-12-03
BR9709889A (pt) 1999-08-10
TR199802240T2 (es) 1999-02-22
IL126591A0 (en) 1999-08-17

Similar Documents

Publication Publication Date Title
AR007004A1 (es) Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen
CO4940465A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
SE9903760D0 (sv) New compounds
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
DE50310516D1 (de) Fredericamycin-derivate
ES2193937T3 (es) Nueva forma cristalina de la sal de potasio de (s) -omeprazol.
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
ES2123149T3 (es) Derivados de perhidroisoindol como antagonistas de la substancia p.
DK0934937T3 (da) Azolderivater som superoxidradikalinhibitor
ATE262519T1 (de) Heterozyklische ether- und thioether-verbindungen,verwendbar zur steuerung von chemischer synaptischer transmission
SV2007002526A (es) Diarilsulfona sulfonamidas y el uso de las mismas ref. p1018
ECSP045221A (es) Sales de valsartan
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
BR0109542A (pt) Derivados de imidazopirina alquilados
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
BR0314112A (pt) Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
SE8304408L (sv) Desoxiuridinderivat, forfaranden for deras framstellning och deras anvendning som lekemedel
ES2092868T3 (es) Utilizacion de derivados de la 4-tiorresorcina en unas composiciones cosmeticas o dermofarmaceuticas de accion despigmentante.
DE69726206D1 (de) Prodrogen von 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-on
CR10690A (es) Nuevos derivados de fluoreno, composiciones que los contienen y utilizacion como inhibidores de la proteina chaperona hsp90
PT952975E (pt) Compostos bi-aromaticos ligados por um radical hetero-etinileno e composicoes farmaceuticas e cosmeticas que os contem
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
AR026337A1 (es) Benzoil-ciclohexanodionas y benzoil-pirazoles, procedimiento para su preparacion y su utilizacion como herbicidas y reguladores del crecimiento de lasplantas
ES2076894B1 (es) Derivados de 2-(4-(4-azolilbutil)-1-piperacinil)-5-hidroxipirimidina, su preparacion y su aplicacion como medicamentos.